JUL 28, 2020 9:00 AM PDT

Laboratory Testing for Viral Hepatitis: what's new and what has changed?

Sponsored by: DiaSorin Inc.
C.E. Credits: P.A.C.E. CE Florida CE
  • Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno
      Dr. Gish was first in Pharmacy School at the University of Kansas and then obtained his medical degree from the University of Kansas Medical School in Kansas City, Kansas. He completed a 3-year internal medicine residency at the University of California, San Diego, and a 4-year gastroenterology and hepatology fellowship at the University of California, Los Angeles which included transplant medicine.

      Dr. Gish is a fellow of the American Association for the Study of Liver Disease, the American Society of Transplantation and the American College of Physicians.

      He has served on the editorial boards of American Journal of Gastroenterology, Hepatology, Journal of Hepatology, Digestive Diseases and Sciences, and Gastroenterology, among many others. He has co-authored a public health policy for liver health in Vietnam focusing on HBV and is also assisting with the development of viral hepatitis health care policies in Georgia, Armenia, and the Philippines. He was a major early contributor to decipherment methods for the detection of hepatitis B and C virus and characterizing its epidemiology and clinical presentation in humans. He was involved in studies that led to the genotypic classification strategies and methods now in use worldwide. He has published more than 700 original articles, review articles, abstracts, and book chapters.

      Robert G. Gish, MD, is currently an Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD and is a Staff Physician at Loma Linda University's Liver Transplant Clinic in Las Vegas. In addition, he is also Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania.


    DATE:  July 28, 2020

    TIME:   9:00 am PDT, 12:00 pm EDT


    The demographic profile of hepatitis B and C has seen a paradigm shift over the last 10 years and as a result clinical guidelines for hepatitis testing are changing. With updated screening recommendations on the way it is necessary to understand the role of serological markers in both diagnosis of hepatitis B virus (HBV) and monitoring HBV disease status.  The best way to reduce the spread of HBV infection and to optimize patient management is through the implementation of robust serological testing; with a few caveats along the way.   
    Learning Objectives:
    • Understand the shift in screening recommendation for hepatitis in the clinical guidelines based on the rise of hepatitis in younger demographics including HBV and HCV
    • Recognize the importance of serological markers for HBV diagnosis and management
    • Identify potential caveats when testing based on serological profiles and the complexity of HBV


    Webinars will be available for unlimited on-demand viewing after live event.


    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.



    Show Resources
    Show Resources
    • See more